![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Keshavarzian Ali Farhadi Ashkan Mutlu Ece A
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.11, Iss.3, 2002-03, pp. : 365-385
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Mesalazine for the treatment of inflammatory bowel disease
Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Thiopurine Treatment in Inflammatory Bowel Disease
Clinical Pharmacokinetics, Vol. 46, Iss. 9, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Recent developments in inflammatory bowel disease therapy
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 7, 1997-07 ,pp. :